Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 is a research paper published in New England Journal of Medicine (2021). On theSindex it has a DataRank of 0. It has been cited 758 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institute of Allergy and Infectious Diseases
Grant: AI149644
National Institute of Allergy and Infectious Diseases
Grant: HHSN272201500002C
National Institute of Allergy and Infectious Diseases
Grant: P51 OD011132
National Institute of Allergy and Infectious Diseases
Grant: UM1AI148373
National Institute of Allergy and Infectious Diseases
Grant: UM1AI148576
National Institute of Allergy and Infectious Diseases
Grant: UM1AI148684
National Institute of Allergy and Infectious Diseases
Grant: UM1Al148684-01S1
National Center for Advancing Translational Sciences
Grant: UL1 TR002243
NIAID NIH HHS
Grant: U01 AI149644
NIAID NIH HHS
Grant: U01 AI151698
National Institutes of Health
Grant: 5UM1AI148576-02
Vaccine and Treatment Evaluation Units
National Institutes of Health
Grant: 3UM1AI148684-03S1
Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG)
National Institutes of Health
Grant: 5UL1TR002243-05
Vanderbilt Institute for Clinical and Translational Research (VICTR)
National Institutes of Health
Grant: 3P51OD011132-64S2
Renovation to expand and enhance NHP housing for HIV/AIDS research at the Emory NPRC
National Institutes of Health
Grant: 1U01AI149644-01
Respiratory Virus Vaccine and Adjuvant Exploration
National Institutes of Health
Grant: 3UM1AI148373-02S1
Kaiser Washington Vaccine and Treatment Evaluation Unit
Children’s Healthcare of Atlanta
Dolly Parton COVID-19 Research Fund
North Carolina Policy Collaboratory at the University of North Carolina at Chapel Hill
Covid-Catalyst-I3 Funds from the Woodruff Health Sciences Center and Emory School of Medicine
Emory Executive Vice President for Health Affairs Synergy Fund award
Georgia Research Alliance
Coalition for Epidemic Preparedness Innovations
Center for Childhood Infections and Vaccines
North Carolina Coronavirus Relief Fund
FWCI
44.17
Citation Percentile
1.0%
Influential Citations
25
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 4 of Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia
Additional file 4 of Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia
Additional file 3 of Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia
Additional file 3 of Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia
Additional file 2 of Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia
Additional file 2 of Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia
Additional file 1 of Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia
Additional file 1 of Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia
Additional file 1 of COVID-19 vaccination intention and vaccine characteristics influencing vaccination acceptance: a global survey of 17 countries
Additional file 1 of COVID-19 vaccination intention and vaccine characteristics influencing vaccination acceptance: a global survey of 17 countries
Additional file 2 of COVID-19 vaccination intention and vaccine characteristics influencing vaccination acceptance: a global survey of 17 countries
Additional file 2 of COVID-19 vaccination intention and vaccine characteristics influencing vaccination acceptance: a global survey of 17 countries
Additional file 3 of COVID-19 vaccination intention and vaccine characteristics influencing vaccination acceptance: a global survey of 17 countries
Additional file 3 of COVID-19 vaccination intention and vaccine characteristics influencing vaccination acceptance: a global survey of 17 countries
Additional file 4 of COVID-19 vaccination intention and vaccine characteristics influencing vaccination acceptance: a global survey of 17 countries
Additional file 4 of COVID-19 vaccination intention and vaccine characteristics influencing vaccination acceptance: a global survey of 17 countries
Additional file 5 of COVID-19 vaccination intention and vaccine characteristics influencing vaccination acceptance: a global survey of 17 countries
Additional file 5 of COVID-19 vaccination intention and vaccine characteristics influencing vaccination acceptance: a global survey of 17 countries
Additional file 6 of COVID-19 vaccination intention and vaccine characteristics influencing vaccination acceptance: a global survey of 17 countries
Additional file 6 of COVID-19 vaccination intention and vaccine characteristics influencing vaccination acceptance: a global survey of 17 countries